Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy

▤ Summary

Aeovian Pharmaceuticals secured an oversubscribed $55 million Series B round to advance AV078, its first-in-class selective mTORC1 inhibitor. The company will use the proceeds to complete a Phase 2 proof-of-concept study in tuberous sclerosis complex-related refractory epilepsy. New and existing investors backed the round, and the company also added two investor representatives to its board. Aeovian is positioning AV078 as a differentiated, CNS-penetrant therapy designed to improve efficacy and tolerability versus current options.

$ Funding

▦ Linked Companies